Highlights SciSparc Ltd.

Equities

SPRC

IL0010951403

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.42 ^USD	+7.58%		+15.45%	-70.90%

Apr. 11	SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd.	CI
Apr. 01	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd.	Apr. 10	CI
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
SciSparc Ltd. Receives Another Patent, Strengthening its Core Technology in Canada	Mar. 18	CI
SciSparc Ltd. Announces Successfully Dosed the First Patient in Its SCI-210 Clinical Trial At the Soroka Medical Center for Pediatric Patients	Mar. 14	CI
SciSparc Ltd. Announces Enrollment of First Patient for Its Clinical Trial for Children with Autism Spectrum Disorder	Mar. 08	CI
Scisparc Ltd. Granted Patent for Core Technology in Multiple Jurisdictions in Europe	Mar. 07	CI
SciSparc Ltd. Receives Canadian Patent for Opioids Reduction Use in Pain Management Technology	Mar. 06	CI
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	Feb. 29	CI
Clearmind Medicine Submits Three International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds	Feb. 27	MT
Clearmind Medicine Submits Three International Patent Applications for Next Generation Psychedelic-Based Compounds	Feb. 20	MT
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder	Jan. 29	CI
SciSparc Ltd. and Clearmind Medicine Inc. Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments	Jan. 04	CI
Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial	Dec. 01	CI
SciSparc Ltd. Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment	Nov. 28	CI
SciSparc Signs Letter of Intent to Merge With Vehicle Importer in Israel	Nov. 22	MT
An unknown buyer signing of a non-binding letter of intent to acquire SciSparc Ltd. in reverse merger transaction.	Nov. 21	CI
SciSparc Ltd. Unveils Positive Topline Results from its Investigator-Initiated Phase IIa Trial At the Sophie & Abraham Stuchynski Israeli Alzheimer's Medical Center	Nov. 15	CI
SciSparc Ltd. Announces Initiation of its Phase IIb Clinical Trial Treatments with its SCI-110, Proprietary Drug Candidate	Nov. 10	CI
SciSparc Ltd. Receives Patent from the Australian Patent Office for Its Reduction of Opioids Use in Pain Management Technology	23-10-31	CI
SciSparc Ltd. Receives Notice of Acceptance for Its Core Technology Application for the Combinations of Cannabinoids and N-Acylethanolamines	23-10-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SciSparc Ltd.

Equities

SPRC

IL0010951403

Highlights

Filters